What type of study is this?

September 12, 20250 citations

Figure 5 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

NSNiccolò G. Santin NSNamrata Sethi SBStefania Bellone

Key Points

Significant tumor growth inhibition was observed in mice treated with Dato-DXd compared to control groups including datopotamab and CTL-ADC.
The median survival for Dato-DXd treatment was unreached, contrasting with 36 days for datopotamab and 32 days for CTL-ADC.
Mice receiving Dato-DXd demonstrated enhanced outcomes, indicating potential as an effective therapy for poorly differentiated endometrial carcinomas.
Further studies are needed to confirm these results and explore the long-term efficacy and safety of Dato-DXd in clinical settings.

Abstract

Antitumor activity in mice inoculated with TROP2 3+ xenograft tumor models. A, PDX TROP2 3+ END(K)265 after one single retro-orbital injection with Dato-DXd compared with controls, including CTL-ADC, datopotamab, and control vehicle. A significant difference in tumor growth inhibition was detected beginning on day 8 (P B, OS of Dato-DXd was compared with the one of datopotamab, CTL-ADC, and control vehicle. The median survival for the Dato-DXd group was unreached, as all mice were alive, compared with 36 days for datopotamab, 32 days for CTL-ADC, and 29 days for control vehicle. C, Mouse weight change during the whole duration of treatment

Ask AI

Helpful

Bookmark

View Full Paper